Friday, November 13, 2020

PDS Biotechnology Corp (PDSB)

3Q Update: Phase 2 Study in Head and Neck Cancer is Initiated

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First company-sponsored Phase 2 study is initiated. PDS Biotechnology reported 3Q results and provided updates on the ongoing progress of its pipeline. The company initiated the first company-sponsored Phase 2 clinical trial VERSATILE 002 assessing PDS0101 in combination with checkpoint inhibitor Keytruda for the treatment of in first-line recurrent or metastatic, HPV16-positive head and neck cancers. Safety data is expected to complete in Q2 2021.

Q3 2020 results.  In 3Q, PDS’s net loss was $3.9 million. In the 9-months of 2020, net loss was $10.9 million, which is in line with our estimates of $14.8 million in operating loss in F2020. The company ended the quarter with $33.5 million in cash and cash equivalents. Earnings per shares (EPS) loss was ($0.23) in the quarter. Updating shares outstanding, we now forecast ($0.91) in EPS in F2020 ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.